|
|
||||||||
J Thorac Cardiovasc Surg 2009;137:1180-1184
© 2009 The American Association for Thoracic Surgery
General Thoracic Surgery |
a Department of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan
b Department of Thoracic Surgery, Tenriyorozu Hospital, Nara, Japan
Received for publication June 10, 2008; revisions received August 18, 2008; accepted for publication September 12, 2008. * Address for reprints: Kotaro Kameyama, MD, Department of Thoracic Surgery, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan. (Email: kk8724{at}kchnet.or.jp).
Objective: The seventh TNM Classification of Malignant Tumours will be published in 2009. The International Association for the Study of Lung Cancer has proposed a revision of the current pathologic staging system. We illustrated the effects of this new system and pointed out potential problems using a retrospective study of surgical cases of non–small cell lung cancer at our institution.
Methods: Subjects were 1532 patients for whom current pathologic staging was possible. These data were migrated into the new staging system. The numbers of patients at various stages determined by using the current and new staging systems were, respectively, as follows: IA (n = 700, n = 700), IB (n = 338, n = 249), IIA (n = 49, n = 164), IIB (n = 129, n = 116), IIIA (n = 204, n = 234), IIIB (n = 77, n = 17), and IV (n = 35, n = 52). Prognoses were compared by using the current and the new systems.
Results: By using the new staging system, 5-year survivals by T classifications were as follows: T1a, 82.6%; T1b, 73.3%; T2a, 63.5%; T2b, 50.1%; T3, 40.6%; and T4, 34.6%. There were significant differences between the new T1a and T1b (P = .0026), T1b and T2a (P = .0027), and T2a and T2b (P = .0062) classifications. In the current system 5-year survivals based on pathologic stages were as follows: IA, 84.8%; IB, 72.9%; IIA, 53.8%; IIB, 53.7%; IIIA, 31.8%; IIIB, 34.0%; and IV, 27.1%. There were significant differences between stages IA and IB (P < .0001) and stages IIB and IIIA (P = .0006). In the new system these were as follows: IA, 84.8%; IB, 75.2%; IIA, 62.4%; IIB, 52.1%; IIIA, 32.4%; IIIB, 15.2%; and IV, 30.6%. There were significant differences between stages IA and IB (P = .0004), IB and IIA (P = .0195), IIA and IIB (P = .0257), IIB and IIIA (P = .0040), and IIIA and IIIB (P = .0399).
Conclusion: Although the outcomes for stages IIIB and IV were reversed, the new pathologic staging system was considered valid based on our single-institution evaluation.
This article has been cited by other articles:
![]() |
H. Igai, N. Matsuura, S. Tarumi, S. S. Chang, N. Misaki, T. Go, S. Ishikawa, and H. Yokomise Clinicopathological study of p-T1aN0M0 non-small-cell lung cancer, as defined in the seventh edition of the TNM classification of malignant tumors Eur J Cardiothorac Surg, June 1, 2011; 39(6): 963 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Suzuki, S. Yoshida, Y. Moriya, H. Hoshino, T. Mizobuchi, T. Okamoto, and I. Yoshino Single T factors predict survival of patients with resected stage-IIB non-small-cell lung cancers Eur J Cardiothorac Surg, May 1, 2011; 39(5): 745 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-E. Strand, H. Rostad, T. Wentzel-Larsen, and C. Von Plessen A population-based evaluation of the seventh edition of the TNM system for lung cancer Eur. Respir. J., August 1, 2010; 36(2): 401 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Sculier, T. Berghmans, and A. P. Meert Update in Lung Cancer and Mesothelioma 2009 Am. J. Respir. Crit. Care Med., April 15, 2010; 181(8): 773 - 781. [Full Text] [PDF] |
||||
![]() |
S. Kligerman and G. Abbott A Radiologic Review of the New TNM Classification for Lung Cancer Am. J. Roentgenol., March 1, 2010; 194(3): 562 - 573. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |